[{"id":"c5926a3c-11fc-4d8b-a13e-2af41702c630","acronym":"","url":"https://clinicaltrials.gov/study/NCT03866382","created_at":"2021-01-18T19:04:09.999Z","updated_at":"2025-02-25T12:37:16.517Z","phase":"Phase 2","brief_title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","source_id_and_acronym":"NCT03866382","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":"","alterations":" ","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 314","initiation":"Initiation: 05/13/2019","start_date":" 05/13/2019","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2025-02-24"},{"id":"9a2be334-2a03-47f4-bac6-d53ac52c474b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05286801","created_at":"2022-03-18T11:54:26.510Z","updated_at":"2025-02-25T14:08:43.679Z","phase":"Phase 1/2","brief_title":"Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors","source_id_and_acronym":"NCT05286801","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TNFA • SMARCB1","pipe":" | ","alterations":" SMARCA4 mutation","tags":["TNFA • SMARCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMARCA4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • tiragolumab (RG6058)"],"overall_status":"Recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 11/17/2022","start_date":" 11/17/2022","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-19"},{"id":"9c0791f2-df06-44ae-99f3-11a3ceff187a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02496208","created_at":"2021-01-18T12:02:15.721Z","updated_at":"2025-02-25T15:10:16.692Z","phase":"Phase 1","brief_title":"Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors","source_id_and_acronym":"NCT02496208","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 152","initiation":"Initiation: 07/22/2015","start_date":" 07/22/2015","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-13"},{"id":"a5409d19-a682-484b-8074-dbc0380cdead","acronym":"","url":"https://clinicaltrials.gov/study/NCT02601950","created_at":"2021-01-17T17:38:36.460Z","updated_at":"2024-07-02T16:35:07.229Z","phase":"Phase 2","brief_title":"A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma","source_id_and_acronym":"NCT02601950","lead_sponsor":"Epizyme, Inc.","biomarkers":" CD34 • SS18","pipe":" | ","alterations":" SMARCA4 mutation","tags":["CD34 • SS18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMARCA4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tazverik (tazemetostat)"],"overall_status":"Completed","enrollment":" Enrollment 267","initiation":"Initiation: 12/22/2015","start_date":" 12/22/2015","primary_txt":" Primary completion: 02/26/2024","primary_completion_date":" 02/26/2024","study_txt":" Completion: 02/26/2024","study_completion_date":" 02/26/2024","last_update_posted":"2024-04-29"},{"id":"e8b0660b-2ef5-478d-99a4-a00b7c8e97b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05347212","created_at":"2022-04-26T13:53:53.510Z","updated_at":"2024-07-02T16:35:20.802Z","phase":"Phase 2","brief_title":"Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla","source_id_and_acronym":"NCT05347212","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" SMARCB1","pipe":" | ","alterations":" SMARCB1 negative","tags":["SMARCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMARCB1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • relatlimab (BMS-986016)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/22/2022","start_date":" 09/22/2022","primary_txt":" Primary completion: 07/16/2027","primary_completion_date":" 07/16/2027","study_txt":" Completion: 07/16/2027","study_completion_date":" 07/16/2027","last_update_posted":"2024-02-06"},{"id":"0e03b96b-6a8e-4062-b8be-5ef1699f84a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03274258","created_at":"2021-01-18T16:10:16.279Z","updated_at":"2024-07-02T16:35:23.075Z","phase":"Phase 2","brief_title":"Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma","source_id_and_acronym":"NCT03274258","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" SMARCB1","pipe":" | ","alterations":" SMARCB1 negative","tags":["SMARCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMARCB1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 12/13/2017","start_date":" 12/13/2017","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2024-01-18"},{"id":"eb78ca75-84dc-42fc-9d06-f04752556eba","acronym":"NCI-2018-01292","url":"https://clinicaltrials.gov/study/NCT03587662","created_at":"2021-01-18T17:38:43.114Z","updated_at":"2024-07-02T16:35:23.938Z","phase":"Phase 2","brief_title":"Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer","source_id_and_acronym":"NCT03587662 - NCI-2018-01292","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" SMARCB1","pipe":" | ","alterations":" SMARCB1 negative","tags":["SMARCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMARCB1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • doxorubicin hydrochloride • Ninlaro (ixazomib) • daunorubicin • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/17/2018","start_date":" 08/17/2018","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2024-01-10"},{"id":"4f2aef18-da49-4f4e-b9b6-2e36297daa60","acronym":"","url":"https://clinicaltrials.gov/study/NCT00027820","created_at":"2021-01-17T23:59:34.270Z","updated_at":"2024-07-02T16:36:52.169Z","phase":"Phase 1/2","brief_title":"Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer","source_id_and_acronym":"NCT00027820","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-B","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 106","initiation":"Initiation: 08/01/2001","start_date":" 08/01/2001","primary_txt":" Primary completion: 09/01/2004","primary_completion_date":" 09/01/2004","study_txt":" Completion: 09/05/2004","study_completion_date":" 09/05/2004","last_update_posted":"2019-12-20"}]